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SELECTION OF THE MONTH 
Big title: Simple, accurate and validated algorithm for hepatic fibrosis 
 
Small titles:  
HCV direct acting antivirals going generic HBVcircle: a novel tool to study cccDNA 
Cirrhosis/cholestasis: New biomarkers for disease severity in PSC 
 
 
Non-invasive fibrosis estimation algorithm 
With the introduction of non-invasive tests, the reliance on liver biopsy to stage liver 





RIPK1 activity in the liver does not mean R.I.P. 
Upon ligand binding, receptor-interacting protein kinase–1 (RIPK1) is recruited to 
tumor necrosis factor receptor superfamily (TNFRSF) and Toll-like receptor (TLR) 
complexes promoting prosurvival and inflammatory signaling. RIPK1 also directly 
regulates caspase-8-mediated apoptosis or, if caspase-8 activity is blocked, RIPK3- 
mixed lineage kinase domain–like protein (MLKL)-dependent necroptosis (a form of 
programmed cell death). Necroptosis is characterized by early loss of plasma 
membrane integrity, leakage of intracellular contents, and organelle swelling. The cells 
dying through necroptosis lack the typical apoptotic characteristics, such as membrane 
blebbing, chromatin condensation, and intranucleosomal DNA cleavage into 180 bp 
DNA laddering, but may show TUNEL positivity. Here, Filliol et al. show that, in the 
liver, lipopolysaccharide (LPS, a Gram-negative bacteria byproduct which a pathogen-
associated molecular pattern (PAMP) is recognized by its TLR and this recognition 
stimulates Kupffer cells to produce and secrete tumor necrosis factor α (TNF-α) which 
engages its cognate TNFRSF. In the absence of RIPK1, TNFRSF engagement by 
TNF-α causes hepatocyte apoptosis. These data reveal the pivotal function of 
RIPK1 in maintaining liver homeostasis in conditions of macrophage-induced 
TNF-α burst in response to LPS (and perhaps other PAMPs) sensing. Since 
RIPK1 inhibition or invalidation can lead to necroptosis and subsequent release of 
danger-associated molecular patterns resulting in systemic inflammation, future 
studies should investigate whether RIPK1 activity is decreased in liver diseases and 
could contribute to the development of systemic inflammation in these diseases. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Erbin promotes HCC, differences between human FGF-19 and its murine 
ortholog FGF-15, DDA failure in active HCC 
Aberrant estrogen receptor-α (ERα) expression and signaling are implicated in the 
development of HCC, but its regulation in HCC remains unknown. Wu et al. were 
interested in the Erbin protein which contains 17 leucine-rich repeats and one PDZ 
domain. They show that Erbin expression is significantly elevated in human HCC 
tissue. This elevated expression of Erbin contributes to tumorigenesis of HCC by 
negatively regulating ERα signaling. Restoring ERα signaling by inhibiting Erbin 
expression enhances the sensitivity of HCC cells to tamoxifen treatment, 
providing a new approach for tamoxifen treatment in HCC. 
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The bile acid receptor (also known as farnesoid X-activated receptor) is encoded by 
NR1H4 (also known as FXR). This receptor is involved in many metabolic processes, 
including the regulation of bile acid, lipid and glucose homeostasis. A significant 
component of bile acid receptor-mediated events is related to induction of the enteric 
endocrine hormone Fibroblast growth factor 19 (FGF-19) or its rodent ortholog, FGF-
15. Zhou et al. compared the properties of human FGF-19 and murine FGF-15 in the 
regulation of hepatocarcinogenesis and metabolism in various mouse models of 
disease. They reveal that, although both hormones repress bile acid synthesis, murine 
FGF15 lacks the profound, weight-independent HbA1c-cell-protective effects 
characteristic of human FGF19 in db/db mice with overt diabetes. More strikingly, 
unlike FGF19, FGF15 does not induce HCC in three mouse models of metabolic 
diseases (db/db, diet-induced obese, and Mdr2-deficient mice). They reveal striking 
species-associated differences between FGF-19 and FGF-15 that may restrict the 
relevance of mouse models for the study of the bile acid receptor/FGF19 
pathway, and underscore the importance of clinical assessment of this pathway, 
with respect to both safety and efficacy, in humans. 
Patients with hepatitis C virus (HCV)-related cirrhosis and HCC can be treated with 
oral direct acting antiviral (DAA) regimens. However, data on the use of DAA's in HCV-
positive patients with HCC are scarce. Prenner et al. here how that the presence of 
active HCC tumor at the initiation of HCV therapy is significantly associated with 
all-oral DAA treatment failure. HCV treatment after curative therapies for HCC 
resulted in excellent sustained virologic response. 
 
NON-ALCOHOLIC FATTY LIVER DISEASE 
Role of Integrin beta-7, MAdCAM-1 and dendritic cells in the pathogenesis of 
NASH.  
There is an urgent need to develop targeted therapies for non-alcoholic steatohepatitis 
(NASH). In particular, it is important to identify drivers of immune cell infiltration in order 
to attenuate the inflammatory response to fatty liver. Two interesting studies in this 
issue of the Journal have identified new molecular and cellular drivers of NASH. In a 
first study, Drescher et al. investigated the role of two molecules potentially implicated 
in neutrophil infiltration as a response to fatty liver (i.e., Integrin beta-7 and Mucosal 
addressin cell adhesion molecule 1 [MAdCAM-1]). By using several transgenic mice 
subjected to animal models of NASH, the authors eloquently demonstrated that while 
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MAdCAM-1 (encoded by Madcam1) promotes steatohepatitis, integrin beta-7 
(encoded by Itgb7, also known as Ly69) unexpectedly exerts protective effects. 
Itgb7-/- mice showed earlier steatohepatitis initiation and significantly stronger fibrosis 
progression while Madcam1-/- mice showed less severe steatohepatitis. The 
interaction of integrin beta-7 and their receptor MAdCAM-1 provides novel targets for 
therapeutic interventions in NASH. In a second study, Heier et al. studied the role of 
CD103+ dendritic cells (DCs). These cells represent a heterogeneous cell population 
among which CD103+ DCs play a significant role in immunity and tolerance. The 
authors used several transgenic animals that lack CD103+ DCs. Metabolic challenge 
to mice lacking CD103+ DCs resulted in the progression of steatosis towards 
steatohepatitis, manifesting in increased influx of inflammatory cells into the 
liver and elevated inflammatory cytokine production of myeloid cells upon 
innate stimuli. Conversely, the adoptive transfer of CD103+ cells to DCs deficient 
animals reversed these observed changes and more importantly could attenuate 
cellular damage and inflammation in established murine steatohepatitis. This important 
study has identified the murine CD103+ cells as a protective DCs subtype that 
influences the pro-anti-inflammatory balance and protects the liver from metabolic 
damage.  
 
HEPATITIS C VIRUS (HCV) INFECTION  
Direct antiviral agents (DAA) in real world revisited, DAA going generic, HCV-
induced NK cell activation results in altered NK-mediated antibody-dependent 
killing 
Evaluation of DAA in the real world setting where patient populations are more diverse 
and complex may provide significant additional information with respect to safety and 
efficacy of the regimens. Calleja and Crespo et al. investigated the two oral DAA 
combination regimens, ombitasvir/paritaprevir/ritonavir plus dasabuvir and 
ledipasvir/sofosbuvir, in a large Spanish national database, which includes almost 
4,000 HCV type 1-infected patients (approximately half of them with cirrhosis). Cure 
rates were high with 96.8% and 95.8%, respectively after 12 weeks of therapy, and a 
similar efficacy rate was seen in the subgroup being eligible for a shorter 8-week 
treatment duration. This real-world study – being one of the largest to-date - 
provides relevant and detailed new information regarding treatment efficacy and 
safety in certain subgroups which includes SAEs and SAE-associated treatment 
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discontinuation rates as well as renal safety comparisons of both regimens but 
also addresses the controversial issue of HCC risk in DAA treated patients with 
cirrhosis. 
Price and access currently limit broadening treatment rates for chronic HCV infection 
worldwide as only few patients from developing countries can afford brand name 
DAAs. Generic DAAs may become a solution for this demanding problem. 
Controversies, however, exist concerning the bioequivalence of generics, and relevant 
studies are missing describing the safety and efficacy of generic ledipasvir-sofosbuvir 
regimens. In this issue of the journal, Zeng et al. reported for the first time the safety 
and efficacy of 8 or 12 weeks of generic ledipasvir-sofosbuvir  ribavirin for 187 
Chinese patients with chronic genotype 1b HCV infection in an observational real-world 
study setting. Although not studied head-to-head, SVR rates of approximately 
97%, which were achieved with the generic ledipasvir-sofosbuvir regimen in all 
treatment groups, were comparable to SVR rates reported with the same brand 
name regimen. Undoubtedly, the broad implementation of low pricing and accessible 
generic DAAs (approximately USD $300 per 28 generic tablets) can dramatically affect 
the global burden of HCV-related diseases, and future validation studies with larger 
number of patients but also shorter treatment durations are warranted. 
The mechanisms involved in immune escape as well as immune control of HCV 
infection are still not well defined. The dual function of natural killer (NK) cells, e.g. 
recognition and killing of target cells, and the coordination of the adaptive immune 
response, made them important players in orchestrating immune responses in chronic 
viral infections, including HCV. The present study by Oliviero and Mantovani et al. 
elegantly examined NK cell CD16 expression and function in patients with chronic HCV 
infection and healthy controls in order to get new mechanistic insights into the effect of 
HCV on its functional modulation. The present study provides for the first time evidence 
that HCV-infection induces NK cell activation, which leads to shedding of their Fc 
receptor for IgG (CD16), an essential molecule for antibody binding, hence resulting in 
altered NK-mediated antibody-dependent killing of target cells. This occurs through the 
action of enzymes named metzincins. This study has important translational 
implications, as it provides clear evidence that virus-induced NK cell activation not only 
impairs IFN production but also alters the efficiency of antibody-dependent killing in 
chronic HCV infection. The new mechanism described here may contribute to HCV 
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persistence and may represent a general phenomenon whereby some viruses can 
escape host’s immune responses. 
 
HEPATITIS B VIRUS (HCV) INFECTION  
HBVcircle: a novel tool to study cccDNA 
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) persists as a stable 
episome in infected hepatocytes and serves as a template for the transcription of all 
viral genes and has become an interesting target for novel therapeutic strategies to 
cure HBV infection. The establishment of an immune-competent mouse model that 
supports persistent cccDNA-dependent HBV replication would greatly facilitate 
preclinical studies aiming for destabilizing cccDNA, and to study HBV-related 
immunopathogenesis. Yan et al. used minicircle technology to generate cccDNA-like 
molecules (called HBVcircle), and characterized the performance of HBVcircle in in 
vitro transfection studies as well as in immunocompetent mice after hydrodynamic 
injection. HBVcircle formed authentic cccDNA-like molecules in vitro and in vivo, 
and supported high levels and persistent HBV replication. Different factors 
affecting in vivo HBV replication and persistence were also studied, including different 
classes of anti-HBV drugs. HBVcircle, a close mimic of cccDNA, represents an 
appealing novel tool for addressing HBV cccDNA-related biological questions, and for 
anti-HBV drug discovery. 
 
NON-INVASIVE FIBROSIS ESTIMATION  
Simple, accurate and validated algorithm for hepatic fibrosis using biochemical 
and fibrosis tests 
With the introduction of non-invasive tests, the reliance on liver biopsy to stage liver 
disease has declined substantially. Boursier et al. performed a hugely important study 
in over 3000 patients to develop and validate an algorithm for assessment of the 
severity of fibrosis using routine biochemical data and many tests of liver fibrosis. The 
newly developed e-LIFT test, which combines routine biochemical data performed the 
best as the first line test. The FibroMeterVCTE (FMVCTE) was the most accurate 
among the eight, fibrosis tests evaluated. The sensitivity of the eLIFT-FMVCTE 
algorithm (first-line eLIFT, second-line FibroMeterVCTE) was 76.1% for 
advanced fibrosis and 92.1% for cirrhosis. The test was also able to provide 
accurate prognostic information. The data would allow to further reduction in the 
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need for liver biopsy. 
 
NOVEL BILIARY PROTEINS IN PRIMARY SCLEROSING CHOLANGITIS (PSC) 
Newly discovered proteins in bile and serum define prognosis, which may serve 
as future therapeutic targets 
Treatment options for PSC patients are limited and the prognosis is also extremely 
difficult to define. Vesterhus et al. performed a study in patients with PSC and 
measured 63 key proteins in the serum and bile of patients with PSC. Twenty-four 
proteins in the bile derivation panel were significantly (P<0.05) different between PSC 
patients with mild compared to severe cholangiographic changes. They observed that 
serum IL-8 provided excellent discrimination for transplant-free survival both in 
the serum derivation and validation cohort. This provides important 
pathophysiological information that may be useful in prognostic models and for 
therapeutic targeting. 
 
